Molecular Devices announces new high sensitivity CatchPoint Cyclic AMP non-radioactive assay kit, pre-packaged for high throughput screening in 384-well plates
Molecular Devices has announced the launch of the CatchPoint Cyclic AMP assay kit.
This kit represents the first of a series of assays that are expected to provide the highest available sensitivity, pre-packaged in a 384-well plate format compatible with high-throughput screening.
Cyclic AMP is an important signaling molecule for drug discovery, but current screening tools are relatively insensitive, expensive, and often use radioisotopes for detection purposes.
The CatchPoint assay is non-radioactive and ten times more sensitive than alternative commercial assays.
The assay is pre-packaged for high throughput screening in 384-well plates, and the novel formulation generates a very robust fluorescent readout that resists interference from drug compounds.
The assay protocol does not require exact temperatures or incubation times, making it well-suited for batch processing or robotic handling.
"In applications where cAMP levels are low, such as drug discovery screens for agonists of Gi-coupled GPCRs, sensitivity is important," stated Stephen Oldfield, marketing director for drug discovery at Molecular Devices.
"This kit provides the highest level of sensitivity available in an HTS format.
With its precise fluorescent readout, the kit leverages Molecular Devices' significant installed base of Analyst, Acquest and Spectramax Gemini microplate readers, providing a solution for all stages in the drug discovery pipeline."
